Guggenheim Capital’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $2.84M | Sell |
58,488
-37,778
| -39% | -$1.84M | 0.02% | 554 |
|
|
2025
Q1 | $3.28M | Buy |
96,266
+9,065
| +10% | +$308K | 0.03% | 521 |
|
|
2024
Q4 | $3.43M | Sell |
87,201
-670
| -0.8% | -$26.4K | 0.03% | 516 |
|
|
2024
Q3 | $4.13M | Buy |
87,871
+34,518
| +65% | +$1.62M | 0.03% | 590 |
|
|
2024
Q2 | $2.88M | Buy |
53,353
+3,385
| +7% | +$183K | 0.02% | 695 |
|
|
2024
Q1 | $3.41M | Buy |
49,968
+14,128
| +39% | +$963K | 0.02% | 690 |
|
|
2023
Q4 | $2.24M | Sell |
35,840
-14,312
| -29% | -$896K | 0.02% | 796 |
|
|
2023
Q3 | $2.28M | Sell |
50,152
-19,313
| -28% | -$877K | 0.02% | 764 |
|
|
2023
Q2 | $3.9M | Sell |
69,465
-5,550
| -7% | -$312K | 0.03% | 607 |
|
|
2023
Q1 | $3.39M | Sell |
75,015
-7,037
| -9% | -$318K | 0.03% | 655 |
|
|
2022
Q4 | $3.34M | Buy |
82,052
+4,403
| +6% | +$179K | 0.03% | 668 |
|
|
2022
Q3 | $5.07M | Buy |
77,649
+4,196
| +6% | +$274K | 0.05% | 498 |
|
|
2022
Q2 | $4.46M | Sell |
73,453
-2,300
| -3% | -$140K | 0.04% | 594 |
|
|
2022
Q1 | $4.76M | Sell |
75,753
-10,186
| -12% | -$639K | 0.03% | 671 |
|
|
2021
Q4 | $6.51M | Buy |
85,939
+20,566
| +31% | +$1.56M | 0.03% | 579 |
|
|
2021
Q3 | $7.32M | Buy |
65,373
+33,651
| +106% | +$3.77M | 0.04% | 502 |
|
|
2021
Q2 | $5.14M | Buy |
31,722
+352
| +1% | +$57K | 0.03% | 668 |
|
|
2021
Q1 | $3.82M | Buy |
31,370
+12,539
| +67% | +$1.53M | 0.03% | 736 |
|
|
2020
Q4 | $2.88M | Buy |
+18,831
| New | +$2.88M | 0.02% | 806 |
|